Last reviewed · How we verify
SHR-A1811, SHR-1316, and 5-FU
SHR-A1811, SHR-1316, and 5-FU is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | SHR-A1811, SHR-1316, and 5-FU |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811, SHR-1316, and 5-FU CI brief — competitive landscape report
- SHR-A1811, SHR-1316, and 5-FU updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about SHR-A1811, SHR-1316, and 5-FU
What is SHR-A1811, SHR-1316, and 5-FU?
SHR-A1811, SHR-1316, and 5-FU is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd..
Who makes SHR-A1811, SHR-1316, and 5-FU?
SHR-A1811, SHR-1316, and 5-FU is developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (see full Suzhou Suncadia Biopharmaceuticals Co., Ltd. pipeline at /company/suzhou-suncadia-biopharmaceuticals-co-ltd).
What development phase is SHR-A1811, SHR-1316, and 5-FU in?
SHR-A1811, SHR-1316, and 5-FU is in Phase 2.